Legislative and Public Policy
Our Legislative and Public Policy team works seamlessly with our firm's top-rated Life Sciences and Healthcare Regulatory practice group to regularly track and advise on virtually every significant pharmaceutical, biotechnology, medical device, and healthcare-related legislation considered on Capitol Hill. Our distinct combination of regulatory and public policy experience provides clients with the most effective advocacy in both offensive and defensive legislative matters. We are leaders in helping our clients anticipate and shape new statutory and regulatory challenges, from user fee legislation to drug and device safety-related investigations, changes to government healthcare programs, and development of new measures to expedite the approval of drugs and devices. We also support clients in efforts to shape state laws such as drug takeback and biologic substitution legislation. We regularly draw from the firm's Life Sciences and Healthcare Regulatory practice, consisting of attorneys, an economist, health care professionals who have served in senior positions on healthcare committees in Congress, scientists, and former leadership from the Centers for Medicare & Medicaid Services (CMS), the US Department of Health and Human Services, and the Congressional Budget Office that have decades of experience providing services to pharmaceutical, biomedical research and development, biotechnology, medical device, and diagnostic companies.